ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced that it has closed a Series C financing raising gross proceeds of approximately $40 million. The financing was led by a new investor along with strong support from current investors, including Venture Investors Health Fund, Arboretum Ventures and Falcon Vision, an ophthalmology investment platform supported by KKR.
Related: Diagnostics startup Noze awarded $1.8m grant for World Tuberculosis Day
Proceeds from this round of financing will ensure the continued advancement of clinical, regulatory, and commercial milestones of the Company’s ViaLase® Laser. If approved, the ViaLase Laser will be the first femtosecond laser used for the treatment of primary open angle glaucoma (POAG).
“ViaLase’s innovative approach to glaucoma management has the potential to elevate the standard of care for glaucoma patients around the world,” said Jim Adox, Executive Managing Director, Venture Investors. “We have strongly believed in ViaLase’s proven leadership, brilliant team, and pioneering technology since we wrote the first seed check to back the team.”
“The strong support from our investors validates the potential of the ViaLase Laser to enhance the current treatment paradigm for the millions of patients living with glaucoma,” said Tibor Juhasz, PhD, Founder and Chief Executive Officer, ViaLase, Inc. “We are preparing to embark on a new phase in our company’s evolution—commercialization —and are incredibly fortunate to have the support, resources, financial backing and counsel of such a high-caliber group of investors.”
The ViaLase Laser combines the precision of femtosecond laser technology and the accuracy of micron-level image guidance to deliver a noninvasive glaucoma treatment called femtosecond laser image-guided high-precision trabeculotomy, or FLigHT. The novel FLigHT procedure will provide physicians with unparalleled precision and visibility when creating channels in the trabecular meshwork (TM) to lower intraocular pressure (IOP) through a noninvasive, nonsurgical approach.
